---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-007230"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:34:05.200257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan

## Summary
- $125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.
- Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.
- Since program authorization in May 2025, ~$160M of common stock repurchased to date.
- CEO states stock is "meaningfully undervalued" relative to business strength and growth trajectory.

## SEC filing metadata
- accession: 0001140361-26-007230
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/0001140361-26-007230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126007230/ef20066774_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-007230
- JSON: https://secwatch.observer/filing/0001140361-26-007230.json
- Plain text: https://secwatch.observer/filing/0001140361-26-007230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.